OBJECTIVE: To investigate the efficacy, potential limitations, and biological mechanisms of UV-A1 phototherapy for skin sclerosis due to collagen deposition disorders. DESIGN: Before-and-after trial of UV-A1 irradiation of sclerotic skin; in vivo biochemical analyses after UV-A1 irradiation of normal skin. SETTING: Academic referral center. PARTICIPANTS: Patients with morphea/scleroderma or sclerodermoid graft-vs-host disease and volunteers without skin disease. Intervention Sclerotic skin was treated with high-dose (130 J/cm(2); n = 12) or medium-dose (65 J/cm(2); n = 6) UV-A1 phototherapy 3 times per week for 14 weeks; normal skin was treated with UV-A1 irradiation at various doses and frequencies, with biopsies performed afterwards. MAIN OUTCOME MEASURES: In sclerotic skin, induration was clinically assessed using a scoring scale. In normal skin, quantitative polymerase chain reaction was used to assess antifibrotic responses, defined as decreased type I and type III procollagen and increased matrix metalloproteinase levels. RESULTS: In patients with sclerotic skin treated with high-dose UV-A1 irradiation, clinical scores for induration modestly decreased. To investigate what factors prevented further improvement (ie, complete clearance), normal skin with light pigmentation was exposed to UV-A1 irradiation (70-150 J/cm(2)) and was assessed for antifibrotic responses. A single high-dose exposure (110-150 J/cm(2)) elicited substantial antifibrotic responses and induced skin darkening. This skin darkening attenuated responses to subsequent UV-A1 exposures and was dose dependent. Thus, to minimize skin darkening, additional patients with sclerotic skin were treated with medium-dose UV-A1 phototherapy, which was no less effective than high-dose therapy. CONCLUSION: Clinical responses of sclerotic skin to UV-A1 phototherapy were modest because of UV-A1-induced skin darkening, which is photoprotective and attenuates antifibrotic responses. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00129415.
OBJECTIVE: To investigate the efficacy, potential limitations, and biological mechanisms of UV-A1 phototherapy for skin sclerosis due to collagen deposition disorders. DESIGN: Before-and-after trial of UV-A1 irradiation of sclerotic skin; in vivo biochemical analyses after UV-A1 irradiation of normal skin. SETTING: Academic referral center. PARTICIPANTS: Patients with morphea/scleroderma or sclerodermoid graft-vs-host disease and volunteers without skin disease. Intervention Sclerotic skin was treated with high-dose (130 J/cm(2); n = 12) or medium-dose (65 J/cm(2); n = 6) UV-A1 phototherapy 3 times per week for 14 weeks; normal skin was treated with UV-A1 irradiation at various doses and frequencies, with biopsies performed afterwards. MAIN OUTCOME MEASURES: In sclerotic skin, induration was clinically assessed using a scoring scale. In normal skin, quantitative polymerase chain reaction was used to assess antifibrotic responses, defined as decreased type I and type III procollagen and increased matrix metalloproteinase levels. RESULTS: In patients with sclerotic skin treated with high-dose UV-A1 irradiation, clinical scores for induration modestly decreased. To investigate what factors prevented further improvement (ie, complete clearance), normal skin with light pigmentation was exposed to UV-A1 irradiation (70-150 J/cm(2)) and was assessed for antifibrotic responses. A single high-dose exposure (110-150 J/cm(2)) elicited substantial antifibrotic responses and induced skin darkening. This skin darkening attenuated responses to subsequent UV-A1 exposures and was dose dependent. Thus, to minimize skin darkening, additional patients with sclerotic skin were treated with medium-dose UV-A1 phototherapy, which was no less effective than high-dose therapy. CONCLUSION: Clinical responses of sclerotic skin to UV-A1 phototherapy were modest because of UV-A1-induced skin darkening, which is photoprotective and attenuates antifibrotic responses. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00129415.
Authors: A Kreuter; T Gambichler; A Avermaete; T Jansen; M Hoffmann; K Hoffmann; P Altmeyer; G von Kobyletzki; M Bacharach-Buhles Journal: Pediatr Dermatol Date: 2001 May-Jun Impact factor: 1.588
Authors: Alexander Kreuter; Frank Breuckmann; Andrea Uhle; Norbert Brockmeyer; Gregor Von Kobyletzki; Marcus Freitag; Markus Stuecker; Klaus Hoffmann; Thilo Gambichler; Peter Altmeyer Journal: J Am Acad Dermatol Date: 2004-05 Impact factor: 11.527
Authors: M Mempel; T Schmidt; K Boeck; K Brockow; S Stachowitz; H Fesq; T Schäfer; S Thomsen; C Schnopp; J Ring; R Probst; P Luppa; D Abeck Journal: Br J Dermatol Date: 2000-03 Impact factor: 9.302
Authors: C J Gruss; G Von Kobyletzki; S C Behrens-Williams; J Lininger; T Reuther; M Kerscher; P Altmeyer Journal: Photodermatol Photoimmunol Photomed Date: 2001-08 Impact factor: 3.135
Authors: G A Okoye; B M Rainer; S G Leung; H S Suh; J H Kim; A M Nelson; L A Garza; A L Chien; S Kang Journal: Br J Dermatol Date: 2014-10-01 Impact factor: 9.302
Authors: Frank Wang; Noah R Smith; Bao Anh Patrick Tran; Sewon Kang; John J Voorhees; Gary J Fisher Journal: JAMA Dermatol Date: 2014-04 Impact factor: 10.282
Authors: Julia V de Albuquerque; Brenda Ng Andriolo; Monica Ra Vasconcellos; Vinicius T Civile; Anne Lyddiatt; Virginia Fm Trevisani Journal: Cochrane Database Syst Rev Date: 2019-07-16